Theranostics and how it works

Theranostics is a treatment using diagnostic imaging to identify if target receptors are present on cancer cells, followed by precision radiation treatment that target these receptors.

 

Who may benefit?

Theranostics can be used to treat cancers that have spread (metastasised), or where cancer is advanced and/or hasn’t responded to other treatments.

While in the future theranostics may be used for different cancers, to date most experience and success has been in metastatic prostate cancer and neuroendocrine tumours.

Metastatic prostate cancer

c

 

How it works

Theranostics is a personalised approach to treating cancer, using both diagnosis and therapy tools as part of the treatment.

Theranostics uses PET scan imaging (a special type of scan) to see if specific targets, known as tumour receptors, are present on tumour cells. If these targets are present and visible on the scan, a radioactive drug is used to treat the tumours. The drug is given as an injection and selectively targets the tumour cells while avoiding healthy areas. Most of the radioactive drug that doesn’t reach the target is quickly passed out of the body.

 

Limited clinical trial evidence is available for the use of theranostics in prostate cancer and the treatment has not yet been reviewed by the Australian Medicines Regulator – The Therapeutic Goods Administration (TGA). Access to treatment is authorised via the TGA Special Access Scheme, a scheme for compassionate access to medicines before registration. It is an out of pocket expense for patients as theranostics is not currently covered by Medicare or private health insurance.

Enquire about theranostics

You can also contact us by calling 08 9438 8500.

 

Different types of theranostics

Lutetium-177 PSMA therapy (Lu-PSMA) is a new treatment for advanced prostate cancer. It delivers high doses of targeted radiation to the cancer sites. It’s used to specifically target the abnormal cells while limiting damage to surrounding healthy tissue .

Read more

Lutetium-177 Octreotate therapy (Lu-Octreotate) is a treatment for advanced neuroendocrine tumours (NETs) or carcinoids.

It delivers high doses of targeted radiation to the cancer sites. It’s used to specifically target the abnormal cells while limiting damage to surrounding healthy tissue. This therapy has been used for almost 20 years in this tumour type and is now approved for the treatment of progressive advanced neuroendocrine tumours in Europe and the USA.

Read more

Radium-223 therapy is an established treatment for prostate cancer that has spread to the bones. It delivers high doses of targeted radiation to the cancer sites . It’s used to specifically target the abnormal cells while avoiding damage to surrounding healthy tissue.

Read more

Iodine-131 therapy is an established treatment for thyroid cancer. It delivers targeted radiation to the affected sites. Iodine-131 is a radioactive form of Iodine that is absorbed by thyroid cells. It targets the cancer cells (including any that have spread, such as to the lymph nodes in the neck). Iodine-131 is also used to treat a hyperactive thyroid gland by helping the overactive thyroid return to normal.

Read more

Yttrium-90 SIR therapy (SIRT) or Selective Internal Radiation Therapy is an established treatment for liver cancer. It delivers high doses of targeted radiation to cancer sites. Yttrium-90 is designed to become lodged in the smaller blood vessels surrounding liver tumours. This means the radioactivity can be precisely targeted, avoiding damage to surrounding healthy tissue.

Read more

Yttrium-90 Radiosynovectomy therapy is an established treatment for painful joints caused by arthritis or other types of joint diseases. Yttrium-90 is injected into the joint, allowing the radiation therapy to precisely target the area. This reduces inflammation (redness and swelling) resulting in less painful joints.

Read more

Samarium-153 EDTMP therapy (Quadramet) is an established treatment for cancer (lung, prostate and breast ) that has spread to the bones. It delivers high doses of targeted radiation to the cancer sites . It allows us to precisely target the abnormal cells while avoiding damage to surrounding healthy tissue.

Lutetium-177 PSMA therapy (Lu-PSMA) is a new treatment for advanced prostate cancer. It delivers high doses of targeted radiation to the cancer sites. It’s used to specifically target the abnormal cells while limiting damage to surrounding healthy tissue .

Read more

Lutetium-177 Octreotate therapy (Lu-Octreotate) is a treatment for advanced neuroendocrine tumours (NETs) or carcinoids.

It delivers high doses of targeted radiation to the cancer sites. It’s used to specifically target the abnormal cells while limiting damage to surrounding healthy tissue. This therapy has been used for almost 20 years in this tumour type and is now approved for the treatment of progressive advanced neuroendocrine tumours in Europe and the USA.

Read more

Radium-223 therapy is an established treatment for prostate cancer that has spread to the bones. It delivers high doses of targeted radiation to the cancer sites . It’s used to specifically target the abnormal cells while avoiding damage to surrounding healthy tissue.

Read more

Iodine-131 therapy is an established treatment for thyroid cancer. It delivers targeted radiation to the affected sites. Iodine-131 is a radioactive form of Iodine that is absorbed by thyroid cells. It targets the cancer cells (including any that have spread, such as to the lymph nodes in the neck). Iodine-131 is also used to treat a hyperactive thyroid gland by helping the overactive thyroid return to normal.

Read more

Yttrium-90 SIR therapy (SIRT) or Selective Internal Radiation Therapy is an established treatment for liver cancer. It delivers high doses of targeted radiation to cancer sites. Yttrium-90 is designed to become lodged in the smaller blood vessels surrounding liver tumours. This means the radioactivity can be precisely targeted, avoiding damage to surrounding healthy tissue.

Read more

Yttrium-90 Radiosynovectomy therapy is an established treatment for painful joints caused by arthritis or other types of joint diseases. Yttrium-90 is injected into the joint, allowing the radiation therapy to precisely target the area. This reduces inflammation (redness and swelling) resulting in less painful joints.

Read more

Samarium-153 EDTMP therapy (Quadramet) is an established treatment for cancer (lung, prostate and breast ) that has spread to the bones. It delivers high doses of targeted radiation to the cancer sites . It allows us to precisely target the abnormal cells while avoiding damage to surrounding healthy tissue.

Theranostics patient journey

Our theranostic specialists

Our theranostic centres

We currently have two centres in Australia offering theranostics treatment for our patients. Visit our centre pages for more information.

Visit Hollywood Private Hospital, WA

Visit Hurstville, NSW